MK-1167 / Merck (MSD), Neuphoria Therapeutics - LARVOL DELTA

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) (clinicaltrials.gov) - P2 | N=369 | Terminated | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Dec 2026 ➔ Jun 2026 | Active, not recruiting ➔ Terminated | Trial primary completion date: Dec 2026 ➔ Jun 2026; Termination Notes: Business reason

Trial completion date • Trial primary completion date • Trial termination • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Merck ends Phase II Alzheimer’s trial of MK-1167 after interim efficacy failure (AllSci Corp) - "Merck said the decision followed a planned interim analysis showing the study failed to meet its efficacy threshold. While the ClinicalTrials.gov registry lists the reason for termination as 'business reasons,' the company said the outcome reflected lack of efficacy rather than any safety concern...Merck said the broader collaboration remains in place despite discontinuation of MK-1167."

Discontinued • P2 data • Trial termination • Alzheimer's Disease

MK-1167, A Positive Allosteric Modulator Of α7 Nicotinic Cholinergic Receptors: Proof-of-biology And Dose Selection For A Clinical Trial (AAIC 2026) - No abstract available

Clinical

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011) (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion

A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010) (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011) (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) (clinicaltrials.gov) - P2 | N=350 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011) (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open

A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010) (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting

Enrollment closed

A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010) (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011) (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P1 trial

MK-1167, a positive allosteric modulator of ?7 nicotinic cholinergic receptors: proof-of-biology, dose selection, and clinical trial design (CTAD 2025) - No abstract available

Clinical

A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010) (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P1 trial

Merck Showcases Data for Alzheimer’s Disease Candidates MK-2214 and MK-1167 at CTAD 2025 (Merck (MSD) Press Release) - "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present first-in-human data for MK-2214 and MK-1167 at Clinical Trials on Alzheimer’s Disease (CTAD) 2025 in San Diego, California from Dec. 1-4."

P1 data • P2 data • Alzheimer's Disease

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) (clinicaltrials.gov) - P2 | N=350 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: May 2027 ➔ Jan 2027 | Trial primary completion date: May 2027 ➔ Jan 2027

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck (GlobeNewswire) - "Neuphoria Therapeutics Inc...announced today that the Company is due to receive a $15 million milestone payment from Merck...The payment is triggered by the initiation, by Merck, of a Phase 2 clinical trial to evaluate the safety and efficacy of MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator (PAM), for the treatment of the symptoms of Alzheimer’s disease dementia (NCT06721156)...This $15M payment marks the second milestone achieved in the collaboration with Merck. Under the agreement, Neuphoria is eligible to receive up to $450M in additional milestone payments for certain development and commercial milestones associated with the progress of multiple candidates plus royalties on net sales of any licensed medicines."

Financing • Alzheimer's Disease • Dementia

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) (clinicaltrials.gov) - P2 | N=350 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) (clinicaltrials.gov) - P2 | N=350 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P2 trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006) (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Merck Sharp & Dohme LLC

New P1 trial

A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004) (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Merck Sharp & Dohme LLC

New P1 trial

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | N=16 ➔ 28

Enrollment change • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P1 trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia